Editor's Note: This  safety study was designed to assess, in a population of elderly residents in nursing homes, clinical and genomic risks associated with Ginkgo biloba leaf extract (GBLE) treatment. This multicentre randomized clinical trial, placebo controlled, double blinded, compared subjects randomized to twice-daily doses of either 120-mg of Ginkgoselect®Plus or to placebo for a six-month period. No adverse clinical effects or increase of liver injury markers were reported in the treatment group and none of the markers investigated revealed a higher risk in the treatment group.

The Journal of Nutrition
10.1186/s12906-018-2080-5
January 22, 2018


Abstract

BACKGROUND:  Numerous health benefits have been attributed to the Ginkgo biloba leaf extract (GBLE), one of the most extensively used phytopharmaceutical drugs worldwide. Recently, concerns of the safety of the extract have been raised after a report from US National Toxicology Program (NTP) claimed high doses of GBLE increased liver and thyroid cancer incidence in mice and rats. A safety study has been designed to assess, in a population of elderly residents in nursing homes, clinical and genomic risks associated to GBLE treatment.

METHODS:  GiBiEx is a multicentre randomized clinical trial, placebo controlled, double blinded, which compared subjects randomized to twice-daily doses of either 120-mg of IDN 5933 (also known as Ginkgoselect®Plus) or to placebo for a 6-months period. IDN 5933 is extracted from dried leaves and contains 24.3% flavone glycosides and 6.1% of terpene lactones (2.9% bilobalide, 1.38% ginkgolide A, 0.66% ginkgolide B, 1.12% ginkgolide C) as determined by HPLC. The study was completed by 47 subjects, 20 in the placebo group and 27 in the treatment group. Clinical (adverse clinical effect and liver injury) and genomic (micronucleus frequency, comet assay, c-myc, p53, and ctnnb1 expression profile in lymphocytes) endpoints were assessed at the start and at the end of the study.

RESULTS:  No adverse clinical effects or increase of liver injury markers were reported in the treatment group. The frequency of micronuclei [Mean Ratio (MR) = 1.01, 95% Confidence Intervals (95% CI) 0.86-1.18), and DNA breaks (comet assay) (MR = 0.91; 95% CI 0.58-1.43), did not differ in the two study groups. No significant difference was found in the expression profile of the three genes investigated.

CONCLUSIONS:  None of the markers investigated revealed a higher risk in the treatment group, supporting the safety of IDN 5933 at doses prescribed and for duration of six months.


For more news from AHPA, follow us on social media:
       
  • link below
The links above are provided as a convenience, however, web pages are often updated by their host sites and this link may not remain active. AHPA gathers information from many organizations. Some sites require you to register in order to read articles.